Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
Dr Jabbour discussed recent phase 3 PhALLCON trial (NCT03589326) data, supporting more potent third-generation tyrosine kinase inhibitor (TKI) ponatinib’s move to the frontline for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Adding ponatinib up front doubled minimal residual disease negativity complete response rates vs standard second-generation TKIs, meeting the primary end point. More patients avoided transplant, with improved event-free survival. Manageable cardiovascular risk was shown with dose adjustment. Dr McCloskey addressed challenges in Ph+ ALL and said selecting optimal TKI therapy is still based on patient factors, but ponatinib’s early activity and favorable safety support its use earlier in therapy to improve outcomes.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More